MOG Antibodies in Pediatric Neurology

Neuropediatrics 2018; 49(01): 001-002
DOI: 10.1055/s-0037-1606545

Editorial Commentary

Georg Thieme Verlag KG Stuttgart · New York

MOG Antibodies in Pediatric Neurology^[*]

Peter Huppke

¹Department of Pediatrics and Pediatric Neurology, University Medical Center Göttingen, Georg August University, Göttingen, Germany

References
1 Hennes E, Baumann M, Lechner C, Rostásy K. MOG spectrum disorders and role of MOG antibodies in clinical practice. Neuropediatrics 2017
2 Jarius S, Ruprecht K, Kleiter I. , et al; In cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13 (01) 280
3 Jarius S, Ruprecht K, Kleiter I. , et al; In cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016; 13 (01) 279